Notably, YTHDC1 is vital for triple-negative breast cancer progression because it increases cancer cell survival and TGF-β-mediated EMT via SMAD3 to promote distant metastasis, highlighting the therapeutic potential of targeting the YTHDC1–m6A–SMAD3 axis [195]. This evidence concerns the gene SMAD3 and triple-negative breast carcinoma.